Hairy cell leukemia variant and WHO classification correspondence Re: 5 th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

Michael Grever,Leslie Andritsos,Mirela Anghelina,Evgeny Arons,Versha Banerji,Jacqueline Barrientos,Seema A. Bhat,James Blachly,Alessandro Broccoli,Timothy Call,Claire Dearden,Sascha Dietrich,Monica Else,Narendranath Epperla,Andrei Fagarasanu,Brunangelo Falini,Francesco Forconi,Alessandro Gozzetti,Paul Hampel,David J. Hermel,Sunil Iyengar,James B. Johnston,Gunnar Juliusson,Robert J. Kreitman,Francesco Lauria,Gerard Lozanski,Christopher C. Oakes,Sameer A. Parikh,Jae Park,Graeme Quest,Kanti Rai,Farhad Ravandi,Tadeusz Robak,Kerry A. Rogers,Alan Saven,John F. Seymour,Tamar Tadmor,Martin S. Tallman,Constantine S. Tam,Enrico Tiacci,Xavier Troussard,Bernhard Wörmann,Clive S. Zent,Thorsten Zenz,Pier Luigi Zinzani

DOI: https://doi.org/10.1038/s41375-024-02280-0

2024-06-09

Leukemia

Abstract:Leukemia - Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

oncology,hematology

What problem does this paper attempt to address?

This paper focuses on a specific type of leukemia called Hairy Cell Leukemia Variant (HCLv) in Chronic Lymphocytic Leukemia (CLL). In the 2022 revision of the classification of hematological and lymphoid neoplasms by the World Health Organization (WHO), HCLv has been eliminated and replaced with a new diagnostic category called Splenic B Cell Lymphoma/Leukemia with Prominent Nucleoli (SBL/LPN), which also includes other rare B-cell malignancies.

As an international team of experts, the authors are concerned that categorizing HCLv under this new category may hinder the identification and development of disease-specific targeted treatment strategies, which are urgently needed to improve patient prognosis. They point out that although HCLv is not a homogeneous clinical entity and lacks a single characteristic molecular marker, certain subtypes have specific molecular targets that could potentially be therapeutic opportunities.

The article discusses the clinical and biological differences between HCLv and classic Hairy Cell Leukemia (HCLc), emphasizing that HCLv patients have poorer treatment response and shorter survival time. HCLv patients respond to purine analogs less effectively than HCLc patients, and durable remission requires more complex combination therapies such as cladribine with rituximab. Since HCLv does not harbor the BRAF V600E mutation, BRAF inhibitors cannot be used for salvage therapy.

The authors urge for widespread collaboration among institutions in the development of new therapies for HCLv to evaluate novel targeted therapies for this rare lymphoma subtype. They believe that maintaining tracking of patients with this rare disease and avoiding the loss of important clinical information due to changes in disease classification are vital for future improvements in the treatment of HCLv.